Tag : Keytruda

Latest News

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10) Source...
Latest News

Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

Newsemia
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

Newsemia
KENILWORTH, N.J., & BRUSSELS–(BUSINESS WIRE)—- $MRK #MRK–Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected,...
Latest News

Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®

Newsemia
MADISON, Wis.–(BUSINESS WIRE)–Promega and Merck enter global collaboration to develop Promega’s microsatellite instability (MSI) as a companion diagnostic for use with Keytruda®. Source link...
Latest News

NOXXON PRÄSENTIERT AKTUELLE KLINISCHE DATEN AUS DER NOX-A12 / KEYTRUDA®- PHASE-1/2-KOMBINATIONSSTUDIE AUF DEM ESMO KONGRESS

Newsemia
BERLIN–(BUSINESS WIRE)–NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch eine gezielte Einwirkung auf die Tumormikroumgebung...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #ESMO19–KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response vs Chemotherapy as Neoadjuvant Therapy in TNBC Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy